Abstract
Oncogenic Ras proteins have been seen as an important target for novel anticancer drugs. Due to the functional role of Ras farnesylation, fanesyltransferase (FTase) inhibition was thought to be a strategy for interfering with Ras-dependent transformation. When farnesylation is blocked, the function of Ras protein is severely impaired because of the inability of the nonfarnesylated protein to anchor to the membrane. Although it has been clearly demonstrated that FTase inhibitors (FTIs) inhibit Ras farnesylation, it is uncertain whether the antiproliferative effects of these compounds result exclusively from the effects on Ras. Moreover, no consensus has been reached as to the relevant targets(s) of FTIs that can explain their mosaic pharmacology. In searching for downstream targets for FTIs effects, CENP-E and CENP-F / mitosin were identified. Different studies showed that the inhibition of farnesylation interferes with CENP-E-microtubule association. In the presence of FTIs, chromosome alignment to the metaphase plate is delayed, suggesting that farnesylated proteins are involved in a step critical to bipolar spindle formation and chromosome alignment. An important question is whether these biological effects might contribute to the chemotherapeutic effects of the FTIs. However, FTIs, triggering the spindle checkpoint, might elevate the rate of cellular missegregation to levels that are incompatible with cell viability, as well as have a reduced (but still significant?) effect on checkpointproficient normal cells. As an example, RPR-115135 induced micronuclei (MN) increase in cancer cells displaying high chromosome instability (CIN) levels, whereas in normal cells it is devoid of activity. Cancer cells showing high CIN level might represent an ideal target for the activity of some FTIs.
Keywords: Increasing Complexity, Farnesyltransferase Inhibitors, Chromosome Instability, Oncogenic, fanesyltransferase (FTase)
Current Cancer Drug Targets
Title: Increasing Complexity of Farnesyltransferase Inhibitors Activity: Role in Chromosome Instability
Volume: 3 Issue: 2
Author(s): Carla Falugi, Sonya Trombino, Pierluigi Granone, Stefano Margaritora and Patrizia Russo
Affiliation:
Keywords: Increasing Complexity, Farnesyltransferase Inhibitors, Chromosome Instability, Oncogenic, fanesyltransferase (FTase)
Abstract: Oncogenic Ras proteins have been seen as an important target for novel anticancer drugs. Due to the functional role of Ras farnesylation, fanesyltransferase (FTase) inhibition was thought to be a strategy for interfering with Ras-dependent transformation. When farnesylation is blocked, the function of Ras protein is severely impaired because of the inability of the nonfarnesylated protein to anchor to the membrane. Although it has been clearly demonstrated that FTase inhibitors (FTIs) inhibit Ras farnesylation, it is uncertain whether the antiproliferative effects of these compounds result exclusively from the effects on Ras. Moreover, no consensus has been reached as to the relevant targets(s) of FTIs that can explain their mosaic pharmacology. In searching for downstream targets for FTIs effects, CENP-E and CENP-F / mitosin were identified. Different studies showed that the inhibition of farnesylation interferes with CENP-E-microtubule association. In the presence of FTIs, chromosome alignment to the metaphase plate is delayed, suggesting that farnesylated proteins are involved in a step critical to bipolar spindle formation and chromosome alignment. An important question is whether these biological effects might contribute to the chemotherapeutic effects of the FTIs. However, FTIs, triggering the spindle checkpoint, might elevate the rate of cellular missegregation to levels that are incompatible with cell viability, as well as have a reduced (but still significant?) effect on checkpointproficient normal cells. As an example, RPR-115135 induced micronuclei (MN) increase in cancer cells displaying high chromosome instability (CIN) levels, whereas in normal cells it is devoid of activity. Cancer cells showing high CIN level might represent an ideal target for the activity of some FTIs.
Export Options
About this article
Cite this article as:
Falugi Carla, Trombino Sonya, Granone Pierluigi, Margaritora Stefano and Russo Patrizia, Increasing Complexity of Farnesyltransferase Inhibitors Activity: Role in Chromosome Instability, Current Cancer Drug Targets 2003; 3 (2) . https://dx.doi.org/10.2174/1568009033482056
DOI https://dx.doi.org/10.2174/1568009033482056 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dendritic Cells: Activation and Maturation - Applications for Cancer Immunotherapy
Current Medicinal Chemistry Advanced In Silico Approaches for Drug Discovery: Mining Information from Multiple Biological and Chemical Data Through mtk- QSBER and pt-QSPR Strategies
Current Medicinal Chemistry Using β-Amino Acids and β-Peptide Templates to Create Bioactive Ligands and Biomaterials
Current Pharmaceutical Design Intersection of MicroRNA and Gene Regulatory Networks and their Implication in Cancer
Current Pharmaceutical Biotechnology Breast Cancer Therapy Based on Melatonin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Supervised Machine Learning Algorithms for Evaluation of Solid Lipid Nanoparticles and Particle Size
Combinatorial Chemistry & High Throughput Screening Potential Efficacy of Some African Plants in Benign Prostatic Hyperplasia and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Expansion of Umbilical Cord Blood for Clinical Transplantation
Current Stem Cell Research & Therapy Neuroprotection by Resveratrol in Diabetic Neuropathy: Concepts & Mechanisms
Current Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery LASP1 in Tumor and Tumor Microenvironment
Current Molecular Medicine The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Interleukin-10: An Anti-Inflammatory and Immunosuppressive Cytokine in the Normal and Pathological Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Diabetes-specific Modulation of Peripheral Blood Gene Expression Signatures in Colorectal Cancer
Current Molecular Medicine The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate
Current Bioactive Compounds Growth and Trophic Factors, pH and the Na+/H+ Exchanger in Alzheimers Disease, Other Neurodegenerative Diseases and Cancer: New Therapeutic Possibilities and Potential Dangers
Current Alzheimer Research Statins, Mevalonate Pathway and its Intermediate Products in Placental Development and Preeclampsia
Current Molecular Pharmacology Bifunctional siRNA Containing Immunostimulatory Motif Enhances Protection Against Pandemic H1N1 Virus Infection
Current Gene Therapy Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets